A Multi-Center Study of Population Pharmacokinetics of Polymyxin B in Critically Ill Patients
Open Access
- 1 February 2026
- journal article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-13
Abstract
To develop a population pharmacokinetics (PPK) model for polymyxin B (PB) in critically ill patients, and propose individualized dosing regimens. Methods: Blood samples were collected from intensive care unit (ICU) patients after the third or subsequent PB doses. The NONMEM software was used to construct a PPK model, with a focus on identifying key covariates influencing drug behavior. Patient-specific dosing strategies and probability of target attainment (PTA) were evaluated using Monte Carlo simulations. Results: A total of 56 ICU patients with 350 blood samples were included. A two-compartment model best described the data, with estimated glomerular filtration rate (eGFR) identified as a significant covariate on clearance (CL). The value of CL was 1.68 L/h. The estimated central compartment volume (V 1) was 14.3 L, the peripheral compartment volume (V 2) was 48.84 L, and the intercompartmental clearance (Q) was 4.67 L/h. The simulation results demonstrated a positive correlation between probability of target attainment (PTA) and maintenance dose (MD) at a fixed first dose (FD) for any given minimum inhibitory concentration (MIC). Conversely, a similar increase in PTA with higher FD was observed when MD was held constant. Furthermore, achieving therapeutic targets required larger dosing regimens in patients with better renal function. Conclusion: PB clearance is influenced by eGFR in critically ill patients. Higher MIC values or preserved renal function necessitate increased dosing. This study provides tailored dosing recommendations for ICU patients based on renal function and MIC.Keywords
This publication has 35 references indexed in Scilit:
- Understanding antimicrobial pharmacokinetics in critically ill patients to optimize antimicrobial therapy: A narrative reviewJournal of Intensive Medicine, 2024
- A retrospective analysis of carbapenem-resistant Acinetobacter baumannii infections in critically ill patients: Experience at a tertiary-care teaching hospital ICUJournal of Intensive Medicine, 2024
- A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patientsClinical Microbiology and Infection, 2023
- Pharmacokinetic/pharmacodynamic adequacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in critically ill, general ward and cystic fibrosis patient populationsInternational Journal of Antimicrobial Agents, 2020
- Population Pharmacokinetics of Polymyxin BClinical Pharmacology & Therapeutics, 2018
- Polymyxins for CNS infections: Pharmacology and neurotoxicityPharmacology & Therapeutics, 2018
- Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?International Journal of Antimicrobial Agents, 2016
- Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensusThe Lancet Infectious Diseases, 2015
- Evaluation of colistin as an agent against multi-resistant Gram-negative bacteriaInternational Journal of Antimicrobial Agents, 2005
- Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programmingComputer Methods and Programs in Biomedicine, 2004